Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):ONLS
АТХ:L.03.A.X Other immunostimulants
Pharmacodynamics:Inactivates free radicals and peroxide compounds. It restores the balance of oxidation-reduction reactions, corrects the activity of the immune system.
The action of the drug is divided into three phases: fast, medium and slow.
The duration of the fast phase is 2-3 days. The detoxification effect develops the day after taking the drug due to the enhancement of antioxidant defense of the body due to increased catalase activity, production of lactoferrin and ceruloplasmin. There is a decrease in the level of cholesterol in the blood and the production of inflammatory mediators due to the termination of the disintegration of arachidonic acid. The activity of transaminases and the level of bilirubin in the blood serum decreases, which indicates the cessation of cytolysis of hepatocytes during toxic or infectious liver damage.
The middle phase lasts for 7-10 days. The reactions of phagocytosis increase, which leads to the death of bacteria and viruses.
The slow phase of the action lasts up to 4 months. There is a restoration of cellular and humoral immunity. The number of specific antibacterial and antiviral antibodies increases, IgAnd with his congenital insufficiency.
The drug increases the sensitivity of tumor cells to chemotherapeutic drugs.
Pharmacokinetics:Instantly absorbed from the injection site and decomposes into constituents of the amino acid.
Indications:It is used for children over 2 years and adults for the purpose of prevention and treatment of acute and chronic infectious and inflammatory diseases, immunodeficiency and toxic conditions.
I.A20-A28.A23 Brucellosis
I.A30-A49.A41 Other septicemia
I.A50-A64.A56.1 Chlamydial infections of the pelvic organs and other urogenital organs
I.B00-B09.B00 Infections caused by the herpes simplex virus [herpes simplex]
I.B15-B19.B18.2 Chronic viral hepatitis C
I.B15-B19.B18.1 Chronic viral hepatitis B without delta-agent
I.B20-B24.B24 Disease caused by human immunodeficiency virus [HIV], unspecified
II.C76-C80.C76 Malignant neoplasm of other and inaccurately marked localizations
Contraindications:Children under two years of age, pregnancy.
Individual intolerance.
Carefully:It is used with caution in people with diseases of the hematopoietic system: lymphogranulomatosis, sarcoma.
Pregnancy and lactation:Recommendations for Food and Drug Administration (US Food and Drug Administration) - The group is not defined, no studies have been conducted. The drug is contraindicated during pregnancy and lactation.
Dosing and Administration:Before chemoradiotherapy: 1 ml 1 time per day for a course of 5-6 injections.
In the case of a tumor: III-IV Stage - 1 ml 1 time per day with a course of 5-7 injections, with a repetition (2-3 times) after 20 days.
Opportunistic infections with infection human immunodeficiency virus: 1 ml every 3 days, for a course of 10-15 injections or suppositories.
For treatment of patients with toxemia, septicotoxemia, septic endocarditis, purulent-septic diseases - 1 ml every 4 days. Course: 7 to 20 injections.
As an adjuvant for vaccination: 1 ml intramuscularly or subcutaneously on the day of vaccination.
The highest daily dose: 1 ml (50 mcg), 1 rectal suppository (100 mcg).
The highest single dose: 1 ml (50 mcg), 1 rectal suppository (100 mcg).
Side effects:Individual intolerance.
Allergic reactions.
Overdose:Not described.
Treatment is symptomatic.
Interaction:The drug is compatible with non-steroidal and steroidal anti-inflammatory drugs.
Special instructions:When treating the drug, a general blood test, a leukocyte formula, is monitored.
The effect of the drug does not depend on the amount of prostaglandin E2.
In the treatment of possible exacerbation in the foci of chronic infection.